Monitoring antiplatelet therapy - What is the best method?

被引:11
作者
Mukherjee, D [1 ]
Moliterno, DJ [1 ]
机构
[1] Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA
关键词
D O I
10.2165/00003088-200039060-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Platelet function tests measure different aspects of platelet function, which include adherence, activation, aggregation and secretion. Clinically, the goal of platelet function testing is to provide information about the platelet contribution to the risk of thrombotic or haemorrhagic events and the optimisation of antiplatelet therapy. The important clinical questions are whether an antiplatelet agent is having the desired effect on platelet inhibition (effectiveness) and whether the patient has sufficient residual platelet function to avoid bleeding (safety). The role of aspirin (acetylsalicylic acid) and thienopyridines is well established in the management of patients with coronary artery disease and in the setting of coronary interventions. The last several years have demonstrated the unequivocal effectiveness of intravenously administered platelet glycoprotein (GP) IIb/lIla antagonists in the management of acute coronary syndromes and in the setting of percutaneous coronary interventions. With the increasing use of these GPIIb/IIIa antagonists, it is becoming more important clinically to measure platelet inhibition with these agents. This paper reviews major techniques and instrumentation for platelet monitoring and discusses the goals of the best method.
引用
收藏
页码:445 / 458
页数:14
相关论文
共 44 条
[1]   In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time [J].
Ammar, T ;
Scudder, LE ;
Coller, BS .
CIRCULATION, 1997, 95 (03) :614-617
[2]   PHARMACOKINETICS AND PHARMACODYNAMICS OF MK-383, A SELECTIVE NONPEPTIDE PLATELET GLYCOPROTEIN-IIB/IIIA RECEPTOR ANTAGONIST, IN HEALTHY-MEN [J].
BARRETT, JS ;
MURPHY, G ;
PEERLINCK, K ;
LEPELEIRE, ID ;
GOULD, RJ ;
PANEBIANCO, D ;
HAND, E ;
DECKMYN, H ;
VERMYLEN, J ;
ARNOUT, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (04) :377-388
[3]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1498
[4]   Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases [J].
Chong, PH .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (22) :2363-2386
[5]   FLOW CYTOMETRIC OBSERVATIONS ON THE IN-VIVO USE OF FAB FRAGMENTS OF A CHIMERIC MONOCLONAL-ANTIBODY TO PLATELET GLYCOPROTEIN IIB-IIIA [J].
CHRISTOPOULOS, C ;
MACKIE, I ;
LAHIRI, A ;
MACHIN, S .
BLOOD COAGULATION & FIBRINOLYSIS, 1993, 4 (05) :729-737
[6]  
Coller BS, 1997, CIRCULATION, V95, P860
[7]  
Coller BS, 1997, J CLIN INVEST, V100, pS57
[8]   A MURINE MONOCLONAL-ANTIBODY THAT COMPLETELY BLOCKS THE BINDING OF FIBRINOGEN TO PLATELETS PRODUCES A THROMBASTHENIC-LIKE STATE IN NORMAL PLATELETS AND BINDS TO GLYCOPROTEINS-IIB AND OR GLYCOPROTEIN-IIIA [J].
COLLER, BS ;
PEERSCHKE, EI ;
SCUDDER, LE ;
SULLIVAN, CA .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 72 (01) :325-338
[9]  
COLLER BS, 1993, J BIOL CHEM, V268, P20741
[10]   Glycoprotein IIb IIIa receptor inhibition in interventional cardiology [J].
Gibson, CM ;
Moynihan, JL ;
Al-Mousa, EN ;
Campsey, M ;
Gandhi, R ;
Murphy, S ;
Mattson, S ;
Ryan, KA ;
Mesley, R ;
Swanson, J ;
Arshad, MN ;
Marble, SJ .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 1999, 7 (03) :287-300